Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

biote: 3 Key Takeaways for Long-Term Investors

Data analytics now target lagging clinics, while medical training aims to keep practitioners engaged across the network.

Biote (BTMD -9.83%) reported stronger-than-expected revenue guidance for 2026 during its Q3 2026 earnings call on November 4, 2026, despite a decline in quarterly revenue. The company anticipates full-year 2026 revenue above $175 million, up from a 9.6% drop to $43.3 million in the latest quarter. This performance was driven by the recall of a January 2026 product, which initially slowed new clinic onboarding and procedure volume.

However, Biote's management is actively using data analytics to identify clinics requiring operational support and to enforce sales team accountability, aiming to reduce clinic attrition and boost procedure volume. The company is also leveraging its investments in data and analytics to prioritize clinics that need the most immediate assistance.

Management is focusing on providing ongoing clinical education and resources to healthcare providers to maintain long-term trust and ensure practitioners view Biote as a reliable source of clinical expertise throughout their relationship with the company. Additionally, procedure volume shows signs of stabilizing across clinics, thanks to a combination of internal manufacturing, expanded field representatives, and clinical education efforts.

While recent trends are encouraging and support the 2026 outlook, there is still work to be done to achieve the desired results. Ultimately, Biote aims to convert clinic relationships into consistent procedure volume across its network to enhance execution and generate stronger financial performance over time.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at fool.com →

More in Finance & Markets

More from Monday 16 November →